Integrin Inhibitors

αvβ1

αvβ3

αvβ5

αvβ6

αvβ8

α5β1

α1β1

α2β1

α4β1

α9β1

αIIbβ3

α4β7

αLβ2

Integrin Inhibitors, Agonists, Antagonists, Modulators, Inducers, Controls & Ligands

Product Name	αvβ1	αvβ3	αvβ5	αvβ6	αvβ8	α5β1	α1β1	α2β1	α4β1	α9β1	αIIbβ3	α4β7	αLβ2	Purity
Cilengitide		αvβ3, IC₅₀: 4 nM (αvβ3-Vitronectin interaction^[2]) αvβ3, IC₅₀: 0.61 nM (^[1])	αvβ5, IC₅₀: 79 nM (αvβ5-Vitronectin interaction^[2]) αvβ5, IC₅₀: 8.4 nM (^[1])			α5β1, IC₅₀: 14.9 nM (^[1])								99.91%
Cyclo(-RGDfK)		αvβ3, IC₅₀: 0.94 nM												99.83%
RGD peptide (GRGDNP)						α5β1								99.83%
FZ1 peptide		αvβ3												99.92%
c-RGD-SH TFA		αvβ3												98.84%
Cyclo(Arg-Gly-Asp-D-Phe-Cys)		αvβ3												98.08%
Bexotegrast	αvβ1, Kd: 3.4 nM			αvβ6, Kd: 5.7 nM										99.74%
Lifitegrast													αLβ2	99.29%
MK-0429	αvβ1, IC₅₀: 1.6 nM (inhibition of fibronectin-binding )	αvβ3, IC₅₀: 2.8 nM (inhibition of vitronectin-binding)	αvβ5, IC₅₀: 0.1 nM (inhibition of vitronectin-binding)	αvβ6, IC₅₀: 0.7 nM (inhibition of LAP-binding)	αvβ8, IC₅₀: 0.5 nM (inhibition of LAP-binding)	α5β1, IC₅₀: 12.2 nM (inhibition of fibronectin-binding)								99.50%
TC-I 15							α1β1, IC₅₀: 23.6 (α1β1 μM α1β1, IC₅₀: 24.4 (α1β1 μM	α2β1, IC₅₀: 0.4 (α2β1 μM α2β1, IC₅₀: 26.8 (α2β1 μM						99.94%
Natalizumab									α4β1					99.10%
Volociximab						α5β1, EC₅₀: 0.2 nM								≥99.0%
BTT-3033								α2β1, EC₅₀: 130 nM
Cyclo(RGDyK)		αvβ3, IC₅₀: 20 nM												99.83%
BIO5192								α2β1, IC₅₀: 1053 nM	α4β1, IC₅₀: 1.8 nM	α9β1, IC₅₀: 138 nM		α4β7, IC₅₀: >500 nM		99.96%
Etrolizumab												α4β7		99.56%
SB-273005		αvβ3, Ki: 1.2 nM	αvβ5, Ki: 0.3 nM											99.94%
Integrin modulator 1									α4β1, IC₅₀: 9.8 nM					99.80%
Maleimide-NOTA				αvβ6										99.69%
RGD peptide (GRGDNP) TFA						α5β1								99.94%
Cyclo(-RGDfK) TFA		αvβ3, IC₅₀: 0.94 nM												99.61%
Lifitegrast sodium													αLβ2	99.20%
TR-14035									α4β1, IC₅₀: 87 nM			α4β7, IC₅₀: 7 nM		99.87%
GSK 3008348 hydrochloride	αvβ1, IC₅₀: 2.83 nM	αvβ3, IC₅₀: 12.53 nM	αvβ5, IC₅₀: 4.00 nM	αvβ6, IC₅₀: 1.50 nM	αvβ8, IC₅₀: 2.26 nM									99.86%
αvβ5 integrin-IN-1			αvβ5, pIC₅₀: 8.2											99.28%
GSK 3008348	αvβ1, IC₅₀: 2.83 nM	αvβ3, IC₅₀: 12.53 nM	αvβ5, IC₅₀: 4.00 nM	αvβ6, IC₅₀: 1.50 nM	αvβ8, IC₅₀: 2.26 nM									98.04%
Cyclo(RGDyK) trifluoroacetate		αvβ3, IC₅₀: 20 nM												99.67%
Firategrast									α4β1			α4β7		99.75%
BIO-1211									α4β1, IC₅₀: 4 nM			α4β7, IC₅₀: 2 μM		99.81%
A20FMDV2				αvβ6, IC₅₀: 3 nM										99.80%
EMD527040				αvβ6, IC₅₀: 6 nM										99.88%
HSDVHK-NH2		αvβ3, IC₅₀: 2.74 nM												99.54%
BIO5192 hydrate								α2β1, IC₅₀: 1053 nM	α4β1, IC₅₀: 1.8 nM	α9β1, IC₅₀: 138 nM		α4β7, IC₅₀: >500 nM		99.96%
α5β1 integrin agonist-1						α5β1, EC₅₀: 1.30 μM			α4β1, IC₅₀: 2.99 μM					99.67%
DSPE-PEG2000-iRGD	αvβ1	αvβ3	αvβ5	αvβ6	αvβ8
GFOGER peptide							α1β1	α2β1						99.53%
DOTA-ADIBO TFA				αvβ6										99.06%
Collagen (bovine skin)							α1β1	α2β1
BOP sodium									α4β1	α9β1				99.25%
DSPE-PEG2000-cRGD		αvβ3
Echistatin		αvβ3				α5β1					αIIbβ3
Echistatin TFA		αvβ3				α5β1					αIIbβ3			99.32%
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2)									α4β1
K34c						α5β1								98.79%
Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA		αvβ3												98.69%
Emvistegrast												α4β7		98.06%
RO0270608									α4β1			α4β7		98.80%
α5β1 integrin agonist-2						α5β1, EC₅₀: 45.98 nM								99.80%
Cyclo(Arg-Gly-Asp-(D-Phe)-Glu)		αvβ3												99.94%
MORF-627				αvβ6, IC₅₀: 1.1 nM
Tadocizumab											GPIIb/IIIa
α4β7 Integrin-IN-2												α4β7, IC₅₀: <5 nM
GREDVGC									α4β1					99.45%
Deethyl-emvistegrast												α4β7
Anti-Integrin αvβ8 Antibody					αvβ8
α4β1 antagonist-1									α4β1, IC₅₀: 15 nM
PAS-003			αvβ5
FSC(PEG4-αvβ6)₃				αvβ6, IC₅₀: 0.69 nM
α4β7 Integrin-IN-1												α4β7
Cyclo(GRGDSPA)		αvβ3
C16Y	αvβ1	αvβ3
KAFDITYVRLKF		αvβ3
TBC-4746									α4β1			α4β7
Levocabastine									α4β1
GW559090									α4β1, Kd: 0.19 nM
Nesvategrast		αvβ3, IC₅₀: 0.6 nM		αvβ6, IC₅₀: 8 nM	αvβ8, IC₅₀: 13 nM
(S,R)-Emvistegrast												α4β7
α4 integrin receptor antagonist 3									α4β1			α4β7
NOTA-Asp2-αvβ6L				αvβ6
α5β1 integrin-IN-1		αvβ3, pIC₅₀: 5.5				α5β1, pIC₅₀: 9.4
αvβ6-IN-2				αvβ6, pIC₅₀: 7.8
CP-664511									α4β1, IC₅₀: 0.52 nM
Orbofiban											GPIIb/IIIa
αvβ6-IN-1				αvβ6, pIC₅₀: 8.1
Emvistegrast axial isomer												α4β7
ATTO 740 NHS ester				αvβ6
Anti-Integrin α5β1 Antibody						α5β1
SU015		αvβ3	αvβ5
Orbofiban acetate											GPIIb/IIIa			98.13%
ME-3277											GPIIb/IIIa
3P-RGD2		αvβ3
R-BC154 acetate										α9β1
SM6.1-azide				αvβ6
ανβ6 Integrin ligand-1				αvβ6
IVL 745									α4β1
Valategrast hydrochloride									α4β1			α4β7
(S)-Deethyl-emvistegrast												α4β7
Cyclic αvβ6				αvβ6
MINT1526A						α5β1
Tri-SM6.1				αvβ6
Cyclo(phg-isoDGR-k)-PEG4-non-cleavable-SAR405838						α5β1
JNJ-26076713		αvβ3, IC₅₀: 2.3 nM	αvβ5, IC₅₀: 6.3 nM
c-RGD-SH		αvβ3
TRAP-14 amide											αIIbβ3
αvβ6 integrin inhibitor 2				αvβ6, IC₅₀: 96.5 nM
T7 Peptide		αvβ3
IPS-05002						α5β1
HMR 1031									α4β1
CLT-28643						α5β1

Name
Email *

	Sorry, but the email address you supplied was invalid.